
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is a promising company with a new ARTEMIS T-cell therapy technology platform that has the potential to unlock new opportunities in the immunology market and effectively treat solid tumors. The company's current focus on developing EB103 for B cell NHL has already shown encouraging results in Phase I trials and the ongoing Phase II trial is expected to provide additional data on treatment efficacy, safety, and market positioning. With a strong pipeline and potential milestone and royalty revenue in the future, Estrella Immunopharma has a positive outlook for financial success.
Bears say
Estrella Immunopharma is facing challenges in generating revenue from milestone and royalty payments despite having a promising pipeline for CD19 and CD22-targeted ARTEMIS T-cell therapies. The recent capital raise has extended their operational runway, but the stock's decline and potential updates on partnering and pipeline prioritization indicate concerns about future dilution. The company has made progress in its clinical and financial positions, but their revenue potential may not align with the current stock valuation.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares